A5091030777- Bladder and Urothelial Cancer Treatments
- Urinary and Genital Oncology Studies
- Cancer Immunotherapy and Biomarkers
- Esophageal Cancer Research and Treatment
- Luminescence and Fluorescent Materials
- Ferroptosis and cancer prognosis
- Porphyrin and Phthalocyanine Chemistry
- Cancer Genomics and Diagnostics
- Genetic factors in colorectal cancer
- Quality and Safety in Healthcare
- Prostate Cancer Diagnosis and Treatment
- Gastric Cancer Management and Outcomes
- interferon and immune responses
- Nanoplatforms for cancer theranostics
- Retinoids in leukemia and cellular processes
- Economic and Financial Impacts of Cancer
- COVID-19 and Mental Health
- Human-Automation Interaction and Safety
- Misinformation and Its Impacts
- Cancer-related Molecular Pathways
- Statistical Methods in Clinical Trials
- Safety Warnings and Signage
- Healthcare Technology and Patient Monitoring
- Biomedical and Engineering Education
- Multiple and Secondary Primary Cancers
UCSF Helen Diller Family Comprehensive Cancer Center
2020-2024
Magee-Womens Research Institute
2024
University of California, San Francisco
2020-2024
University of Pittsburgh
2023
University of California, Berkeley
2019
Healthwise
2016
Fluorophores based on the BODIPY scaffold are prized for their tunable excitation and emission profiles, mild syntheses, biological compatibility. Improving water-solubility of dyes remains an outstanding challenge. The development water-soluble usually involves direct modification fluorophore core with ionizable groups or substitution at boron center. While these strategies effective generation fluorophores, they challenging to implement when developing BODIPY-based indicators: can disrupt...
Enfortumab vedotin (EV) is a novel antibody-drug conjugate approved for advanced urothelial cancer (aUC) refractory to prior therapy. In the Urothelial Cancer Network Investigate Therapeutic Experiences (UNITE) study, authors looked at experience with EV in patient subsets of interest which activity had not been well defined clinical trials.UNITE was retrospective study patients aUC treated recently agents. This initial analysis focused on EV. Patient data were abstracted from chart reviews...
Background Immune checkpoint inhibitors (ICI) can achieve durable responses in a subset of patients with locally advanced or metastatic urothelial carcinoma (aUC). The use tumor genomic profiling clinical practice may help suggest biomarkers to identify most likely benefit from ICI. Methods We undertook retrospective analysis treated an ICI for aUC at large academic medical center. Patient and histopathological variables were collected. Responses treatment assessed all least one...
Tumor mutational burden (TMB) and APOBEC signatures are potential prognostic markers in patients with advanced urothelial carcinoma (aUC). Their utility predicting outcomes to specific therapies aUC warrants additional study.We retrospectively reviewed consecutive UC cases assessed UCSF500, an institutional assay that uses hybrid capture enrichment of target DNA interrogate 479 common cancer genes. Hypermutated tumors (HM), defined as having TMB ≥10 mutations/Mb, were also for signatures,...
Cognitive bias is the tendency to subconsciously change ones actions or thought process based on someone else’s comments behavior. It important consider cognitive when performing a usability study because it can significantly alter impair validity of results. While cannot always be entirely eliminated, identifying key biases which results are particularly susceptible first step mitigating them. Once experimenters alert these subtle traps, they approaches that sidestep and greatly improve...
The COVID-19 pandemic dramatically impacted society and health care on a global scale. To capture the lived experience of patients with prostate cancer family members/caregivers during pandemic, we performed mixed-methods study posts to two online networks. We compared all 6187 Inspire Us TOO Prostate Cancer support discussion community from December 2019 April 2020, 6926 same interval in 2019, applying linguistic ethnography method. A similar analysis was using data Reddit website (246 260...
e16510 Background: Patients (pts) with muscle-invasive bladder cancer (MIBC) ineligible for cisplatin-based chemotherapy have no standard systemic therapy options and are prioritized radical cystectomy (RC) alone. This prospective clinical trial investigated the safety efficacy of escalating doses neoadjuvant atezolizumab (N-ATZ) prior to RC in MIBC pts. Methods: is a single-institution, phase II N-ATZ (1200 mg IV every 3 weeks) pts MIBC. Key inclusion criteria were resectable urothelial...
443 Background: Enfortumab vedotin (EV) is an antibody-drug conjugate targeting Nectin-4, which FDA approved for patients (pts) with treatment-refractory advanced urothelial cancer (aUC). The activity of EV in pt subsets interest such as those distinct histological variants has not been well defined. Methods: A retrospective study pts aUC treated ≥1 dose standard care (SOC) or on a clinical trial (if results already reported) at 12 US sites was undertaken. Objective response rate (ORR)...
442 Background: For patients (pts) with muscle-invasive bladder cancer (MIBC) who are ineligible for cisplatin-based chemotherapy (cisplatin), the standard of care option is radical cystectomy (RC) alone. This prospective clinical trial investigated safety and efficacy escalating doses atezolizumab (ATZ) as neoadjuvant therapy prior to RC in pts non-metastatic urothelial cancer. Methods: single-arm, single institution, phase II administration one (n = 6), two 5) or three 9) cycles ATZ (1200...
602 Background: There are no current standard of care options for patients (pts) with muscle-invasive bladder cancer (MIBC) ineligible cisplatin-based chemotherapy (cisplatin). This trial investigated the safety and efficacy escalating doses neoadjuvant atezolizumab (ATZ) prior to radical cystectomy (RC) (NCT02451423). Methods: single-arm, single institution, phase II treatment 1 (n=6), 2 (n=6) or 3 (n=11) cycles ATZ (1200 mg IV every weeks) in pts MIBC. Key inclusion criteria were...
Abstract Senescent cells have a unique senescence-associated secretory profile (SASP) and understanding SASP has contributed to numerous advances in knowledge on aging cancer biology. Quiescence, which is an important yet poorly understood mechanism for chemoresistance, related but distinct from senescence. Quiescence shares non-proliferative feature with senescence reversible state quiescent can reenter the cell cycle. We hypothesized that, analogous senescent cells, quiescence-associated...
2592 Background: Pembrolizumab (pembro) is an intravenous immune checkpoint inhibitor used for anti-cancer treatment, with equivalent monotherapy dosing options of 200 mg every 3 weeks (Q3W) or 400 6 (Q6W). Pembro Q6W was approved use in April 2020 after the Q3W dose had already been established. As pembro patterns real-world practice are not well-described, we evaluated this a large cancer center network consisting central site (CS) and 36 community sites (NS). Methods: We retrospectively...
e17025 Background: Bladder cancers (BC) are frequently highly mutated. Next generation sequencing (NGS) can both shed light on mutational burden and the specific alterations that provide insights into underlying biology of individual tumors. Methods: We retrospectively reviewed BC cases assessed with UCSF500, an institutional NGS assay uses hybrid capture enrichment target DNA to interrogate approximately 500 mutated cancer genes. Hypermutated tumors were defined as having TMB > 10...
Out-of-the-box experience is an important consideration in medical device design that not only impacts the user’s impression of product, but can also have critical safety implications. This article discusses basic questions to contemplate a use-related risk analysis pertaining out-of-the-box experience, and focuses on how most risks be reduced or eliminated by conducting usability study related experience.
Fluorophores based on the BODIPY scaffold are prized for their tunable excitation and emission profiles, mild syntheses, biological compatibility. Improving water-solubility of dyes remains an outstanding challenge. The development water-soluble usually involves direct modification fluorophore core with ionizable groups or substitution at boron center. While these strategies effective generation fluorophores, they challenging to implement when developing BODIPY-based indicators: can disrupt...
476 Background: Reliable predictive markers are lacking in patients (pts) with locally advanced or metastatic urothelial carcinoma (aUC) treated immune checkpoint inhibitors (ICI). We sought to determine whether specific genomic alterations could be used predict overall survival (OS) this patient population. Methods: undertook a retrospective cohort study of pts aUC who received ICI and underwent profiling by next-generation sequencing (NGS). All NGS using commercially available platforms...